Drug intelligence / Profile preview

bupropion + venlafaxine

Development stage
Preclinical
Lead developer
GSK
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Oral
01

Overview

Bupropion + venlafaxine is a combination of two antidepressant medications, each with distinct mechanisms of action. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) and also acts as a non-competitive antagonist at nicotinic acetylcholine receptors. Venlafaxine is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI). The combination has been used off-label in cases of treatment-resistant major depressive disorder, where monotherapy with either agent or other antidepressants was insufficient. Clinical reports suggest that the combination can act synergistically to reduce depressive symptoms and improve social functioning in patients who have not responded to other treatments[1][3]. Co-administration increases extracellular dopamine more than either drug alone, which may contribute to its efficacy[8]. However, this combination carries an increased risk for adverse effects such as seizures and serotonin syndrome; careful monitoring is required[2][5][7].

02

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on bupropion + venlafaxine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupropion + venlafaxine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call